医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate: Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

2017年08月01日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & SAN FRANCISCO & TOKYO

According to life science commercial intelligence firm, Evaluate, the enforcement of a much more stringent pricing revision policy in Japan, both for new products as well as off-patent brands, is behind the decline of the products currently on the market which are forecast to drop about 2% annually in sales through 2022.

The prices of Gilead’s hepatitis C virus (HCV) blockbusters Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS’ novel PD-1/PD-L1 agent.

However, the sales decline of marketed products is counterbalanced by the optimism surrounding new therapies coming to market expected to account for 34% of sales in 2022, among the top ranking are Dupixent (Sanofi), Ibrance (Pfizer), Entresto (Novartis), Aducanumab (Biogen), and Emicizumab (Chugai).

Evaluate recently launched consensus drug forecasts for the Japanese market revealing new insights on the future outlook of the country’s Pharma & Biotech sector for benchmarking and market analysis. For more information and to download the topline marketed and R&D forecast to 2022 in Yen and USD visit: www.evaluate.com/JapanDrugForecasts.

###

About Evaluate

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information, please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epvantage. On Instagram: Evaluateltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005900/en/

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren
+1
617-866-3906
christine.lindgren@evaluategroup.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Harris/Melanie Toyne Sewell
+44
(0) 20 7457 2020
evaluate@instinctif.com
or
Jani
Communications (for U.S. media)
Janice Foley
+1-617-823-5555
janifoley@verizon.net
or
Edelman
Japan KK (For Japanese media)
Yamada/Masaki
TEL: +81(3)-4360-9000
evaluatejapanpr@edelman.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application
  • 火山噴火で家屋の破壊と住民の避難が続く中、ハワイ・コミュニティ財団が支援基金を創設
  • Octapharma宣布Nuwiq®产品新增剂量规格在欧洲获准,提高了血友病A患者的给药灵活性
  • PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始
  • LG化学举办“全球创新大赛 (GIC)”“寻找改变世界的创新技术”